A Phase I/II Open Label Clinical Trial Assessing Safety and Efficacy of Intravesical Instillation of VPM1002BC in Patients With Recurrent Non-muscle Invasive Bladder Cancer After Standard BCG Therapy
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs BCG vaccine (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Aug 2017 Planned End Date changed from 1 Oct 2023 to 31 Dec 2022.
- 25 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 30 Oct 2019.